Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 3Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Stomach Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumor 1Prostatic Neoplasms 1Melanoma 1Carcinoma, Transitional Cell 1Advanced Solid Tumors 1Adenocarcinoma of the Stomach 1

Interventions

Cyclophosphamide 77Docetaxel 69Capecitabine 64Trastuzumab 61Paclitaxel 50Tamoxifen 47Epirubicin 47Letrozole 44pyrotinib 40Fulvestrant 37Doxorubicin 35Vinorelbine 33Radiotherapy 32Carboplatin 32Anastrozole 28exemestane 27Neoadjuvant Therapy 24Drug Therapy 22Fluorouracil 21palbociclib 20Exercise 20Chemotherapy, Adjuvant 19Bevacizumab 18pertuzumab 16Goserelin 16Cisplatin 16liposomal doxorubicin 15Mammography 14Gemcitabine 14Blood Specimen Collection 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms × tesetaxel × Clear all
NCT01221870 2012-07-24

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Genta Incorporated

Phase 2 Unknown
81 enrolled
Breast

Breast Neoplasms

NCT01609127 2012-06-01

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Genta Incorporated

Phase 2 Unknown
213 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡